NUT carcinoma in children, adolescents and young adults

Titre traduit de la contribution: Carcinome NUT chez l'enfant, l'adolescent et le jeune adulte

Lauriane Lemelle, Antoine Moya-Plana, Benoît Dumont, Brice Fresneau, Anne Laprie, Line Claude, Sophie Deneuve, Camille Cordero, Gaelle Pierron, Vincent Couloigner, Sophie Bernard, Liesbeth Cardoen, Hervé J. Brisse, Nina Jehanno, Lucy Metayer, Paul Fréneaux, Sylvie Helfre, Fréderic Kolb, Juliette Thariat, Yves RéguerreDaniel Orbach

    Résultats de recherche: Contribution à un journalBrève enquêteRevue par des pairs

    5 Citations (Scopus)

    Résumé

    Background: NUT carcinoma (NC), defined by the presence of the NUTM1 rearrangement, is an aggressive tumour associated with poor prognosis. This rare cancer is underdiagnosed and difficult to treat. Objective and methods: The primary objective of this review is to describe the clinical, radiological and laboratory features of NC in young patients. The secondary objective is to propose a consensual strategy for the French very Rare Tumour group (FRACTURE group). Results: NUT-specific antibody immunostaining in cases of undifferentiated or poorly differentiated carcinoma may demonstrate the specific NUT gene rearrangement. NCs are frequently advanced stage at diagnosis and the outcome remains poor despite a global strategy that generally includes conventional combination chemotherapy with wide local therapy (surgery, radiotherapy). Chemosensitivity is frequently only transient. Conclusion: Recent data have shown that new targeted drugs (histone deacetylase and bromodomain and extra-terminal protein inhibitors) are promising, but their role has yet to be evaluated in NC. Centralized data review is necessary to improve our knowledge of paediatric NC. We propose a multimodal strategy based on published data and their personal experience.

    Titre traduit de la contributionCarcinome NUT chez l'enfant, l'adolescent et le jeune adulte
    langue originaleAnglais
    Pages (de - à)491-504
    Nombre de pages14
    journalBulletin du Cancer
    Volume109
    Numéro de publication4
    Les DOIs
    étatPublié - 1 avr. 2022

    Contient cette citation